Amylin analog weight loss drugs are moving through trials at Lilly, AstraZeneca, AbbVie, Novo Nordisk, and Pfizer, but none is FDA-approved yet. This article covers how amylin works, how it differs from GLP-1 therapy, and where each candidate stands in the pipeline.
June 2026 delivered a wave of new clinical data and regulatory updates that clarify the path forward for medical weight management. From the ACP’s new prescribing hierarchy to the launch of the Medicare GLP-1 Bridge and the rising potency of multi-agonists, the need for structured, physician-led care has never been more urgent.
Hair shedding is one of the most commonly reported but least-addressed sequelae of GLP-1-related weight loss, and it often overlaps with menopausal female pattern hair loss in the same patient. Aesthetic providers who can identify both presentations and offer structured interventions have a meaningful clinical and practice expansion opportunity.
BMI alone misses many high-risk patients. OBSCORE, a new Nature Medicine tool validated in approximately 200,000 participants, gives medical weight management providers a more precise framework for prioritizing interventions.
Medical weight management providers have already figured out that the real revenue expansion in GLP-1 programs comes from the body contouring services layered on after significant weight loss. Aesthetic providers — already equipped with the skills and tools to serve these patients — are only starting to catch on.
May 2026 brought a wave of new clinical data and market shifts that underscore a critical reality: prescribing a GLP-1 is only the beginning of obesity care. From managing the “off-ramp” of weight regain to addressing the complex reality of muscle mass changes, the need for structured, physician-led weight management programs has never been clearer.
April 2026 brought a wave of regulatory and clinical developments that GLP-1 providers need to act on before summer. From a landmark FDA compounding proposal to the Medicare GLP-1 Bridge program’s July 1 launch, here is what changed and what it means for your practice.
March 2026 delivered some of the most consequential GLP-1 news of the year — from a sweeping FDA enforcement action against telehealth compounders to the approval of Foundayo, the first oral GLP-1 with no food or water restrictions. Here’s what every provider needs to know this month.
February 2026 brought a wave of GLP-1 developments relevant to providers running or building a medical weight loss practice — from the expanding oral treatment landscape and a tightening regulatory environment around compounded alternatives, to new clinical evidence on nutritional deficiencies and muscle loss in long-term users. This month’s update covers what the research says and what it means for how you structure and deliver care.
January 2026 brought major GLP-1 updates, from the launch of the first oral Wegovy pill to a new federal insurance model that contrasts sharply with growing state-level restrictions. This roundup synthesizes the key clinical and regulatory news, providing practice-focused takeaways on what providers need to know about the evolving landscape.
Terms and conditions apply. Offer expires September 30.